Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone When Administered Concurrently in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone When Administered Concurrently in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cudetaxestat (Primary) ; Nintedanib (Primary) ; Pirfenidone (Primary)
  • Indications Cholangitis; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Kidney disorders; Liver disorders; Non-alcoholic steatohepatitis; Scleroderma
  • Focus Pharmacokinetics
  • Acronyms DDI
  • Sponsors Blade Therapeutics

    • Most Recent Events

    • 04 Sep 2022 According to a Blade Therapeutics media release, results from multiple phase I trials [NCT04146805, NCT04814472, NCT04939467 and NCT04814498] presented at European Respiratory Society (ERS) International Congress 2022
    • 04 Sep 2022 Results from multiple phase I trials [NCT04146805, NCT04814472, NCT04939467 and NCT04814498] published in the Blade Therapeutics Media Release
    • 22 Aug 2022 According to a Blade Therapeutics media release, data from four completed phase 1 studies[NCT04146805, NCT04814472, NCT04939467 and NCT04814498] will be presented at the at the European Respiratory Society (ERS) International Congress 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top